Status:
UNKNOWN
OPTImal PHARMacological Therapy for Patients With Heart Failure: The OPTIPHARM-HF Registry
Lead Sponsor:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Collaborating Sponsors:
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Centro Cardiologico Monzino
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Prospective, observational, multicenter, national study of adult patients with HF to assess prescription and adherence to evidence-based Guideline-Directed Medical Therapy (GDMT) in patients with Hear...
Detailed Description
Prospective, observational, multicenter, national study designed to evaluate the care and outcomes of patients with HF, to understand reasons for lack of implementation of evidence-based treatment and...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old
- Signed patient informed consent form (ICF)
- Diagnosis of chronic or acute decompensated HF according to ESC guidelines and the universal definition of HF.
- Receiving at least one drug for management of HF at study enrollment (including diuretics, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists).
Exclusion
- Planned participation or participation in a clinical trial;
- Life expectancy \< 1 year because of non-cardiac causes;
- Previous heart transplant or left ventricular assist device implantation.
Key Trial Info
Start Date :
July 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06192524
Start Date
July 18 2022
End Date
October 1 2025
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST Spedali Civili
Brescia, Italy, 25123